Log In
Print
BCIQ
Print
Print this Print this
 

ATX-MS-1467

  Manage Alerts
Collapse Summary General Information
Company Apitope International N.V.
DescriptionVaccine containing 4 synthetic peptides derived from human myelin basic protein
Molecular Target Major histocompatibility complex class I (MHC)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase I/II
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat relapsing forms of multiple sclerosis (MS); Treat relapsing multiple sclerosis (MS); Treat secondary progressive multiple sclerosis (SPMS)
Regulatory Designation

Partner

Merck KGaA


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today